Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
about
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular diseaseAnti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animalsAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose ControlThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisAnimal models of diabetic macrovascular complications: key players in the development of new therapeutic approachesDipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protectionDipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.The nonglycemic actions of dipeptidyl peptidase-4 inhibitorsExendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes.Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis.Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.Sitagliptin downregulates retinol-binding protein 4 and upregulates glucose transporter type 4 expression in a type 2 diabetes mellitus rat model.Effect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.Isoliquiritigenin Attenuates Atherogenesis in Apolipoprotein E-Deficient MiceThe DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Altered vascular smooth muscle function in the ApoE knockout mouse during the progression of atherosclerosis.The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives.Direct cardiovascular effects of glucagon like peptide-1.Antiatherothrombotic effects of dipeptidyl peptidase inhibitors.Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents:Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in ratsA Double-Blinded Randomized Study Investigating a Possible Anti-Inflammatory Effect of Saxagliptin versus Placebo as Add-On Therapy in Patients with Both Type 2 Diabetes And Stable Coronary Artery Disease.Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice.Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways.Sitagliptin attenuates high glucose-induced alterations in migration, proliferation, calcification and apoptosis of vascular smooth muscle cells through ERK1/2 signal pathway.Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model.The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation.
P2860
Q26741067-EBC7E352-D6B8-4482-83E3-E2466B39B654Q26749176-67D933BD-4E0B-4D49-82F4-C5280995FE26Q26750746-1C981E48-C79C-4888-A5CB-0116C85E6FB4Q26795473-5F245B5E-3725-4DBA-A277-2FEF54CB1446Q26822630-78C4C246-B740-476C-982B-2CAFAAF76EB8Q27011819-79FB1AFE-3E19-4A1B-A9B0-A6E4FB3C59C5Q33883879-A5A1CAAB-5075-43E8-A7A3-8612FDC90C50Q34029715-CDC632CE-35D0-46EF-819E-0BC133D305DFQ34603269-6892ECB0-454B-43E5-84D8-F62572CD132FQ35268563-7B6D7FF9-4A5D-4ABB-ACA9-1D99E7535650Q35413944-4F56D8D0-C604-4966-B1A7-9D44B2BAF908Q36063048-7F37CF93-90C5-4691-B1F0-AF939B966143Q36411670-46AFD4B1-4177-4506-9989-5067E72EF3AFQ36448319-FCA44BAF-9E12-4205-8F42-A83104D74CA0Q36901072-036F4C39-4C0E-45E5-8917-67D387F5158EQ37465715-06A38714-DD1F-4541-AC62-0742BC7750B3Q37562145-4BC58154-6E75-4613-A1A7-9EC05AD8D054Q37611715-E70D87CA-28F7-4FCD-B965-10F60FE6B688Q37720179-261A2F44-5375-4A18-A8E4-191636699A47Q38104293-899735F2-200F-4F87-B424-CDAADD8FCF81Q38132470-71036781-E621-4F35-BE90-051DB79B4668Q38195527-E2E44D85-9FC8-43F1-A07A-7489782CB642Q38199984-8165842F-5875-42BE-9BD4-281D79122767Q38371242-ED3C928A-8453-4540-9B64-67F80C7C7BA6Q38413395-433B68DB-C427-469B-A41A-5E2265F0310CQ38922177-CEF80BDD-0D35-4408-9655-00FFBA591A22Q41097981-C7350CDC-1839-4263-A300-D29FFB418878Q41873186-0417276F-A797-4FA5-B780-C45579A32F92Q41974896-0B1C6AA5-157F-4E7A-BA6B-024C5722A9BAQ42293087-DDD86610-263F-47A1-A6AB-C4CD547DB95FQ46611689-8CDF5866-65D8-43E3-B7B6-40F8F7F4DDD2Q47097583-260CF585-5D6B-4F68-89B9-8ADEBF69FA85Q47247138-F4BC52FA-4057-43BD-8066-380986F27DFDQ48103910-4D298F13-4DED-49CE-847D-2FA82E24F1F4Q48250188-9E5F0B62-A78F-485D-A976-5CE765429536Q50994560-877F2970-491E-41D2-B752-E327E3CA2099Q55467227-A7CE3A96-25AF-4982-A3C1-5A77DC700A32
P2860
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Sitagliptin reduces plaque mac ...... (-/-) mice.
@en
Sitagliptin reduces plaque mac ...... teriosclerotic lesions in Apoe
@nl
type
label
Sitagliptin reduces plaque mac ...... (-/-) mice.
@en
Sitagliptin reduces plaque mac ...... teriosclerotic lesions in Apoe
@nl
prefLabel
Sitagliptin reduces plaque mac ...... (-/-) mice.
@en
Sitagliptin reduces plaque mac ...... teriosclerotic lesions in Apoe
@nl
P2093
P2860
P1433
P1476
Sitagliptin reduces plaque mac ...... (-/-) mice
@en
P2093
A Liberman
M Burgmaier
R Ostertag
P2860
P2888
P304
P356
10.1007/S00125-012-2582-5
P577
2012-05-18T00:00:00Z